Olezarsen (TRYNGOLZA) Sales Forecast and 7MM Market Size Analysis - 2034 | FDA Approval and Hypertriglyceridemia Expansion Unlock Growth Beyond Rare FCS
Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Olezarsen Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The "Olezarsen Sales Forecast, and Market Size Analysis - 2034" report delivers a comprehensive assessment of olezarsen across approved and potential indications, including Hyperlipoproteinaemia type I, familial chylomicronemia syndrome (FCS), and Hypertriglyceridaemia. The analysis covers the seven major markets (7MM): the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan for the study period 2020 -2034.
The report examines historical and current market performance, projected olezarsen sales, pricing and reimbursement trends, regulatory milestones, research and development activities, competitive positioning, patent considerations, and potential generic entry. It also includes SWOT analysis, analyst perspectives, market growth drivers and barriers, and an assessment of late-stage emerging therapies that could influence future commercial performance.
Key Factors Supporting Olezarsen Market Growth
Recent Olezarsen Development
In March 2025, Ionis Pharmaceuticals entered into a licensing agreement granting Sobi exclusive rights to commercialize olezarsen in countries outside the US, Canada and China for FCS and severely elevated triglycerides. Ionis retained independent commercialization rights in the U.S. This agreement expands the product's international commercial infrastructure while supporting continued development in broader triglyceride-related indications.
Olezarsen Product and Clinical Assessment
Olezarsen is a liver-targeted, GalNAc-conjugated antisense oligonucleotide designed to reduce APOC3 production through selective degradation of APOC3 mRNA. Administered by subcutaneous injection, it has demonstrated sustained reductions in triglycerides and apoC-III across clinical studies. Ongoing development programs are assessing its efficacy, safety, and potential impact on pancreatitis risk in patients with severe lipid disorders.
The report provides detailed clinical trial intelligence for approved and potential indications, including trial interventions, conditions, status, enrollment, and start and completion dates. It also evaluates dosage and administration, mechanism of action, regulatory designations, development milestones, and expected launch timelines across the 7MM.
Market Forecast and Competitive Intelligence
Report Methodology
The olezarsen market report is developed using internal databases, primary research, secondary research, and in-house analysis by industry experts. Sources include global regulatory authority websites, clinical trial registries, company disclosures, trade journals, white papers, industry publications, trade associations, industry portals, news platforms, and subscription databases.
Strategic Value of the Olezarsen Market Report
The report supports pharmaceutical companies, investors, healthcare stakeholders, and strategy teams seeking to evaluate olezarsen's commercial potential through 2034. It addresses the product's clinical differentiation, competitive landscape, regulatory trajectory, geographic expansion, pricing outlook, and adoption potential. The analysis also identifies the late-stage therapies most likely to affect market share and provides a structured view of opportunities and risks across approved and potential indications.
Key questions addressed include olezarsen's mechanism of action, clinical and commercial performance, trial status by indication, regulatory designations, collaboration and licensing activity, forecasted sales across the 7MM, cost-effectiveness, duration of therapy, regional cost variations, and competition from marketed and emerging therapies.
Key Topics Covered:
1. Report Introduction
2. Olezarsen Overview in approved indications like Hyperlipoproteinaemia type I; as well as potential indication like Hypertriglyceridaemia
2.1. Product Detail
2.2. Olezarsen Clinical Development
2.2.1. Olezarsen Clinical studies
2.2.2. Olezarsen Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Olezarsen Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Olezarsen Therapies)
5. Olezarsen Market Assessment
5.1. Olezarsen Market Outlook in approved and potential indications
5.2. 7MM Analysis
5.2.1. Olezarsen Market Size in the 7MM for approved and potential indications
5.3. Country-wise Market Analysis
5.3.1. Olezarsen Market Size in the United States for approved and potential indications
5.3.2. Olezarsen Market Size in Germany for approved and potential indications
5.3.3. Olezarsen Market Size in France for approved and potential indications
5.3.4. Olezarsen Market Size in Italy for approved and potential indications
5.3.5. Olezarsen Market Size in Spain for approved and potential indications
5.3.6. Olezarsen Market Size in the United Kingdom for approved and potential indications
5.3.7. Olezarsen Market Size in Japan for approved and potential indications
6. Olezarsen SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/q28jsb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.